PT  - JOURNAL ARTICLE
AU  - Henry Chrystyn
AU  - Sergi Pascual
AU  - Jan Feimer
AU  - Anthony De Soyza
AU  - Jaume Sauleda Roig
AU  - John Haughney
AU  - Laura Padullés
AU  - Beatriz Seoane
AU  - Ludmyla Rekeda
AU  - Anna Ribera
TI  - Preference, satisfaction and critical errors with Genuair<sup>®</sup> and Breezhaler<sup>®</sup> in patients with COPD
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P928
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P928.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P928.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - BackgroundPatient preference and satisfaction with their inhaler and inhaler technique can influence treatment adherence and long-term outcomes in patients with COPD.AimTo assess overall patient preference, satisfaction and correct use of Genuair® vs Breezhaler® after 2 weeks of daily use.MethodsThis was a randomised, cross-over, multicentre study in patients with moderate to severe COPD. Patients consecutively inhaled placebo via Genuair® and Breezhaler® once daily for 2 weeks in addition to their current medication. The primary endpoint was percentage of patients who preferred Genuair® after 2 weeks (Patient Satisfaction and Preference Questionnaire [PASAPQ]). Other endpoints included patient satisfaction, percentage of patients making ≥1 critical error and willingness to continue using each inhaler after 2 weeks.Results The safety population included 127 patients (mean±SD age 68±8 years; male 72%; mean±SD % predicted FEV1 49±13%). Results after 2 weeks of inhaler use are shown in the table.ConclusionsPatient preference, satisfaction and willingness to continue using the inhaler were significantly higher with Genuair® versus Breezhaler®. The proportion of patients who made ≥1 critical error with only one device was low with both inhalers and was numerically higher with Breezhaler® compared with Genuair®.